S&P Futures
3,813.75-3.00(-0.08%)Dow Futures
31,268.00+32.00(+0.10%)Nasdaq Futures
12,658.00-23.75(-0.19%)
BioDelivery Sciences International, Inc. (BDSI)
4.0600 0.00 (0.00%)
Pre-Market: 9:19AM EST
Chart Events
Performance Outlook
| Previous Close | 4.2200 |
| Open | 4.2300 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 1400 |
| Day's Range | 4.0300 - 4.2301 |
| 52 Week Range | 2.8500 - 5.4500 |
| Volume | 880,889 |
| Avg. Volume | 1,082,840 |
| Market Cap | 410.511M |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | 26.54 |
| EPS (TTM) | 0.1530 |
| Earnings Date | Mar 10, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
Fair Value
Related Research
- Zacks
Earnings Preview: BioDelivery Sciences International (BDSI) Q4 Earnings Expected to Decline
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
RALEIGH, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full year 2020 financial results before the open of the U.S. financial markets on Wednesday, March 10, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information: Date: Wednesday, March 10, 2021Time:8:30 AM Eastern TimeDomestic:877-407-0789International:201-689-8562Conference ID:13715530Webcast:http://public.viavid.com/index.php?id=143193 About BioDelivery Sciences International, Inc.BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation. © 2021 BioDelivery Sciences International, Inc. All rights reserved. Contact:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com
- GlobeNewswire
BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President
Brings Track Record of Success to Expanded RoleRALEIGH, N.C., Feb. 11, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer. “Terry has been a key contributor to the Company’s strong performance during her tenure at BDSI, even more so through the uncertainties of the past year with the pandemic, and she has a proven record of success,” said Jeff Bailey, CEO of BDSI. “Her leadership across all aspects of the business, including strategy, talent development and operations, along with her expanded responsibilities, is greatly valued and will be an increasingly important asset to the Company as we advance into our next growth stage.” Terry joined BDSI as CFO in January 2019. Under Terry’s stewardship and teamwork, the Company has achieved profitability and strengthened its balance sheet. She has also led a number of key initiatives, including streamlining and improving processes and systems, as well as improving planning, reporting and controls, to name just a few. With more than 30 years of experience as a multinational finance leader and executive across various industries, Terry has demonstrated excellence in leading major change initiatives, turnarounds, and startups. She has held various senior finance and general management positions at companies including Balchem Corporation, Diversey, Inc., Novartis and Mars Inc. Terry holds an MBA in Finance from IBMEC in Brazil and a BA in both Economics and International Relations, summa cum laude, from The American University School of International Service in Washington, DC. She has led women’s employee resource groups (ERGs) and is a founding Steering Committee Member of the CFO Leadership Council – Charlotte chapter. ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC. BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation. Contact: Terry CoelhoExecutive Vice President and Chief Financial OfficerBDSI_IR@bdsi.com Bob YedidLifeSci Advisors(646) 597-6989bob@lifesciadvisors.com
